News

Latest news

Hide mandatory notifications of trade

Bionor Pharma ASA announces share capital increase due to warrant exercise

(Oslo, Norway, 13 December 2016) Reference is made to the announcement on 1 December 2016 regarding exercise of warrants.

BIONOR PHARMA ASA
STOCK EXCHANGE ANNOUNCEMENT

The share capital of the Company was increased by NOK 862.40 as a consequence of the warrant exercise. The new share capital of the Company has now been registered in the Company Register (Foretaksregisteret). The Company’s new share capital is NOK 138,567,772.10 divided into 1,385,677,721 shares with a par value of NOK 0.10.

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Further information
Einar J. Greve, Chairman of the Board, Bionor Pharma ASA 
E-mail: ejg@cipriano.no Cell Phone: +47 900 27 766

Unni Hjelmaas, Acting Chief Executive Officer, Bionor Pharma ASA
E-mail: uh@bionorpharma.com Cell Phone: +47 915 19 651 

Announcement in pdf